This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
The publisher estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.
In the same year, the publisher estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5-19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.
Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with only one drug in Phase III and one in the NDA/BLA stage.
Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.
High-impact upcoming events for drugs in the obesity space comprise a decentralized EU approval and an estimated EU patent expiration for Qsymia; an expected supplemental CHMP opinion and a PDUFA date for Ozempic; and topline Phase III trial results for tirzepatide.
The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 9.1 years in the overall metabolic space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.
The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 82 trials.
Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
Key Topics Covered:
RECENT EVENTS AND ANALYST OPINION
Tesomet for Obesity (November 23, 2020)
AM833 for Obesity (June 18, 2020)
Ozempic for Obesity (June 12, 2020)
Ozempic for Obesity (June 4, 2020)
Ozempic for Obesity (May 13, 2020)
Tesomet for Obesity (April 22, 2020)
Efpeglenatide for Obesity (December 10, 2019)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Review Vouchers: Danyelza, Imcivree Earn; Novo Nordisk Spends
Rhythm's Setmelanotide Loses Fast-Track Status In Europe
MAAs Under Review/Rhythm Files Setmelanotide
EMA Considers Fast-Tracking Rhythm's Insatiable Hunger and Obesity Disorders Drug
Three Fast Track Drugs Stand Out In Flurry Of Submissions
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Senda Teams With Nestle Nutritional Health For Metabolic Conditions
CMS Pays $35m For China Rights To Gelesis Obesity Therapy
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
For more information about this report visit https://www.researchandmarkets.com/r/hcek0l
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005485/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900